Therapeutic effect and molecular mechanism of the ultra-low molecule compound K on multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is an incurable plasma cell cancer primarily affecting individuals over 60.
• While novel treatments have improved MM prognosis, challenges remain for recurrent/refractory cases, especially concerning age and drug toxicity.
• There is a growing need for new, low-toxicity therapeutic agents for multiple myeloma management.

Purpose of the Study:

• To evaluate the efficacy of KBB-N1, an ultra-low molecular weight ginsenoside compound K, in treating multiple myeloma.
• To investigate the mechanism of action of KBB-N1, specifically its effect on phosphorylated p53 expression.
• To assess the safety and toxicity profile of KBB-N1 in preclinical models.

Main Methods:

• The study involved treating multiple myeloma models with KBB-N1.
• Expression levels of phosphorylated p53 were analyzed.
• Toxicity assessments were performed on hematopoietic stem cells and major organs.

Main Results:

• KBB-N1 demonstrated effective treatment of multiple myeloma.
• Treatment with KBB-N1 led to increased expression of phosphorylated p53.
• KBB-N1 exhibited minimal toxicity to hematopoietic stem cells and major organs.

Conclusions:

• KBB-N1 is an effective therapeutic agent for multiple myeloma.
• The mechanism involves the upregulation of phosphorylated p53.
• KBB-N1 represents a promising, low-toxicity treatment option for older patients with multiple myeloma.